Computer-assisted evaluation of antibiotic regimen coverage and cost

被引:7
作者
Day, D [1 ]
Lubowski, TJ [1 ]
Yamaga, CC [1 ]
Main, J [1 ]
Van Vleet, J [1 ]
Ambegaonkar, A [1 ]
机构
[1] Pfizer Inc, Clin Pharm Outcomes Res, Pfizer Pharmaceut Grp, New York, NY 10017 USA
关键词
D O I
10.1016/S0149-2918(99)80042-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Evaluation of the cost-effectiveness of antibiotic regimens has become an essential part of drug selection for pharmacists and physicians. However, these evaluations can be complicated, time-consuming, and, if the data used are not based on local conditions, misleading. The computer pro gram Dare to Compare 98 was developed to provide an analysis of empiric antibiotic regimens. The Infectious Disease Challenge portion of the program lists the commonly identified pathogens in specific infectious diseases. The Antibiogram Susceptibility Reports section generates susceptibility reports based on local antibiogram data or data from institutions nationwide that have similar demographic profiles. Susceptibility information is combined with cost data in the Quality/Cost Index section. Comparison of the quality and cost index values allows the user to determine which regimens provide the optimal microbiologic activity and cost values for treatment of a particular infectious disease based on local data. Thus Dare to Compare 98 can help pharmacists and physicians evaluate antibiotic regimens and their suitability for inclusion in formularies and disease-management algorithms.
引用
收藏
页码:1418 / 1425
页数:8
相关论文
共 14 条
[1]  
*AM THOR SOC, 1995, J RESP CRIT CARE MED, V153, P1711
[2]  
BOHNEN JMA, 1992, ARCH SURG-CHICAGO, V127, P83
[3]   The future - Can we learn from the past? [J].
Craig, WA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 27 (1-2) :49-53
[4]  
DallaCosta T, 1996, ANN PHARMACOTHER, V30, P1024
[5]   Multidrug resistance - A sign of the times [J].
Levy, SB .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (19) :1376-1378
[6]   PREDICTIVE VALUE OF SUSCEPTIBILITY TESTS FOR THE OUTCOME OF ANTIBACTERIAL THERAPY [J].
LORIAN, V ;
BURNS, L .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 25 (01) :175-181
[7]  
MANDELL GL, 1995, PRINCIPLES PRACTICE, P53
[8]  
MANDELL GL, 1996, PRINCIPLES PRACTICE, P46
[9]  
Nicolle LE, 1996, INFECT CONT HOSP EP, V17, P119
[10]   GUIDELINES FOR THE INITIAL MANAGEMENT OF ADULTS WITH COMMUNITY-ACQUIRED PNEUMONIA - DIAGNOSIS, ASSESSMENT OF SEVERITY, AND INITIAL ANTIMICROBIAL THERAPY [J].
NIEDERMAN, MS ;
BASS, JB ;
CAMPBELL, GD ;
FEIN, AM ;
GROSSMAN, RF ;
MANDELL, LA ;
MARRIE, TJ ;
SAROSI, GA ;
TORRES, A ;
YU, VL .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 148 (05) :1418-1426